Back

Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

31 August 2019 (11:18 - 11:36)
Organised by:
Congress Presentation Part of: New frontiers: SGLT2 inhibitors in cardiorenal disease Antidiabetic Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Associate Professor Thomas A Zelniker

Medical University of Vienna, Vienna (Austria)

4 More presentations in this session

Presentation thumbnail
State of the Art - SGLT2 inhibitors in cardiovascular disease
Professor M. Sabatine (Boston, US)
Slides Video
Presentation thumbnail
Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial
Doctor J. Udell (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes
Doctor C. Noergaard (Aalborg, DK)
Abstract Slides Video
Presentation thumbnail
Integrating SGLT2 inhibitors in diabetes treatment: a guide for cardiologists
Professor N. Sattar (Glasgow, GB)
Slides Video

Access the full session

Session thumbnail
New frontiers: SGLT2 inhibitors in cardiorenal disease

The Event

Event poster

ESC Congress 2019

31 August 2019 11:18 CET
You may be interested in
thumbnail
Congress Presentation
Predictors of worsening kidney function and their relation to SGLT2 inhibitor dapagliflozin administration in type 2 diabetes mellitus patients with chronic heart failure
thumbnail
Congress Presentation
Prevention of new-onset heart failure and renoprotective effect with sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease
thumbnail
Congress Presentation
Canagliflozin in patients with type 2 Diabetes and CKD experiencing deterioration in eGFR to <20 ml/min/1.73m2 in the CREDENCE Trial

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources